zealand pharma glp 1 Roche, shares fall on 'undifferentiated' obesity drug results Novo and Lilly contender Zealand

10.2337/dc14-2883 17 DaviesM.FrchL.JeppesenO

Step 4: Ongoing Support You gain 24/7 access to our team

This study highlights how medications developed for metabolic disease may have far broader implications for oncology

Hansen, K

'While we cannot rule out [developments] 20 years from now', Pottegard told Medscape, 'we can say that we do not see the same short-term association that others have reported.' The researchers concluded that 'studies with longer follow-up are needed'

Your doctor may recommend adjustments to your treatment plan, referral to a specialist (endocrinologist, urologist, gynecologist, or sexual health counselor), or additional interventions to address underlying causes